Ceribell, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Ceribell, Inc. on November 24, 2025. The company is incorporated in Delaware and trades on the Nasdaq Global Select Market under the symbol CBLL. Ceribell is designated as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a regulatory event rather than financial performance data.
Material Changes
The primary material event reported is the U.S. Food and Drug Administration (FDA) granting 510(k) clearance for Ceribell's Clarity 510(k) algorithm. This algorithm is designed for detecting electrographic seizures in newborns, including preterm infants.
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) detailing the FDA clearance. No specific financial guidance, forward-looking outlook, or discussion of risks and contingencies is included in the text of this 8-K. The clearance represents a significant regulatory milestone for the company's product portfolio.
Investor Verification Checklist
- Verify the specific clinical indications and limitations of the newly cleared Clarity 510(k) algorithm.
- Review the attached press release (Exhibit 99.1) for details on commercial availability and market impact.
- Check subsequent filings for any financial impact or revenue recognition related to this clearance.
- Confirm the company's status as an emerging growth company and any associated reporting exemptions.